사지 골수염 치료용 항생제 장치의 핵심 임상시험 - 젠탁신 함유 Genex. (ADOPT GG)
사지 골수염의 외과적 치료의 일부로서 Genex G의 안전성과 유효성을 평가하기 위한 다기관, 단일군, 역사적 대조군 중대 임상 시험.
The purpose of this trial is to determine if genex with gentamicin (genex G) an antibiotic loaded bone void filler, works to treat and is a safe option as part of the surgical treatment of osteomyelitis in the extremities.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
상세 설명
This trial is a multi-center, single arm, historically controlled, pivotal device study.
All participants diagnosed with osteomyelitis of the extremities (Cierny-Mader Classification grades I-IV) can be considered. All participants will undergo surgical debridement and will receive genex with gentamicin (genex G) antibiotic loaded bone void filler as part of the surgical treatment of osteomyelitis of the extremities. Participants will receive antibiotics per site specific requirements as clinically indicated. All participants will be followed up for 24 Months.
연구 유형
연구 유형
등록 (추정된)
등록
단계
단계
- 해당 없음
연락처 및 위치
연구 연락처
연구 연락처
- 이름: Keira Watts, PHD
- 전화번호: +44 (0)1782 338580
- 이메일: clinicaltrials@biocomposites.com
연구 연락처 백업
- 이름: Simal Trikam
- 이메일: strikam@mcra.com
연구 장소
-
-
California
-
San Diego, California, 미국, 92104
- 아직 모집하지 않음
- North Park Podiatry
-
수석 연구원:
- Trent Brookshier, DPM
-
연락하다:
- Trent Brookshier, DPM
- 이메일: trentbrookshier@gmail.com
-
연락하다:
- Vanessa Enriquez
- 이메일: venriquez.npp@gmail.com
-
-
Indiana
-
Indianapolis, Indiana, 미국, 46278
- 모병
- OrthoIndy
-
연락하다:
- Melanie Glover
- 이메일: mglover@orthoindy.com
-
연락하다:
- Kimberly Fitzpatrick
- 이메일: kifitzpatrick@orthoindy.com
-
수석 연구원:
- Sandeep Soin, MD
-
-
Maryland
-
Baltimore, Maryland, 미국, 21215
- 모병
- Sinai Hospital Baltimore
-
수석 연구원:
- Janet Conway, MD
-
연락하다:
- Nathaniel Helwig
- 이메일: nhelwig@lifebridgehealth.org
-
연락하다:
- Sara Orem
- 이메일: sorem@lifebridgehealth.org
-
-
New Jersey
-
Oradell, New Jersey, 미국, 07649
- 모병
- Curalta Clinical Trials
-
연락하다:
- Radhika Gajera
- 이메일: rgajera@curalta.com
-
수석 연구원:
- Vincent Giacalone, DPM
-
연락하다:
- Harrison Miller
- 이메일: hmiller@curalta.com
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
-
Patient with osteomyelitis of the extremities, who have failed antibiotic therapy and are requiring surgical intervention (unresolved osteomyelitis), Cierny-Mader classification of osteomyelitis grades I-IV. Patients presenting with Cierny-Mader grades I-II will be required to have a defect created as part of debridement surgery
-
Patients at least 18 years of age *1
-
Patient willing and able to provide written informed consent
-
Patient geographically stable and able to comply with the required follow-up visits and testing schedule as assessed by the investigator
-
Ability to achieve adequate surgical soft tissue coverage of the wound (primary tissue closure or surgical reconstruction including local and free soft tissue transfer)
- 1 Patients between 18 and 22 years of age require confirmation of skeletal maturity as validated by radiographs of the bone to be treated.
Exclusion Criteria:
- Patients diagnosed with acute osteomyelitis
- Patients with Cierny-Mader grades I-II who are unable to have a defect created during debridement surgery
- Renal failure or documented chronic kidney disease with serum creatinine ≥3.5 mg/dL (309umol/L) or being treated with dialysis
- Participants with a terminal or palliative diagnosis (e.g. terminal cancer diagnosis) deemed to have less than 1 year life expectancy by their health care team
- Uncontrolled diabetes mellitus (hemoglobin A1c levels >10%)
- Pre-existing calcium metabolism disorder
- Women who are pregnant or breastfeeding or planning on becoming pregnant during the study (a pregnancy test will be done in women of childbearing potential at screening and on the day of surgery)
- History of hypersensitivity or contraindication to the investigational device or any of its ingredients (calcium phosphate, β-tricalcium phosphate, and aminoglycoside antibiotics)
- Participation in an investigational drug/device study (within the last 60 days) or prior enrolment to the ADOPT GG study
- Clinically significant or unstable medical or surgical condition that in the investigators opinion may preclude safe and complete study participation (for example patients medically unfit for surgery, general anesthesia, or any risk of significant blood loss resulting in significant risk to loss of life)
- Current untreated malignant neoplasm(s), or current treatment with radiation therapy or chemotherapy
- Current or recent history (within last 2 years) of active substance abuse (e.g. recreational drugs, narcotics, or alcohol) that meets DSM-5 severe criteria
- Currently incarcerated
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 해당 없음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
실험적: Single Arm
Participants will receive genex with Gentamicin, an antibiotic loaded bone void filler that supports bone healing, as part of the surgical treatment of osteomyelitis of the extremities. |
genex with gentamicin will be implanted during debridement surgery |
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
No further requirement for antibiotic treatment due to persisting symptoms of infection at the index site (i.e., additional antibiotics prescribed following completion of the initial systemic antibiotics prescribed post surgery.
기간: Month 12
|
Further requirement for antibiotic treatment due to persisting symptoms of infection at the site of treatment will be assessed at Month 12. |
Month 12
|
|
No further surgical interventions required due to infection at the index site.
기간: Month 12
|
Need for further surgical interventions required due to infection at the index site will be assessed at Month 12. |
Month 12
|
|
No recurrence of sinus formation at the index site.
기간: Month 12
|
Recurrence of sinus formation at the index site will be assessed by a non-contrast CT scan at week 2 & Month 12. Clinical endpoint assessments will also be used to measure this at post operative follow-up visits and will be assessed at Month 12. |
Month 12
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
No additional requirement for antibiotic treatment due to persisting symptoms of infection at the treatment site, i.e., additional antibiotics prescribed following completion of the initial systemic antibiotics prescribed post-surgery.
기간: Month 24
|
Further requirement for antibiotic treatment due to persisting symptoms of infection at the site of treatment will be assessed at Month 24. |
Month 24
|
|
No radiographic evidence of post op fractures.
기간: Month 24
|
Radiographic evidence of post-operative fractures will be evidenced by X-ray & CT evaluations and assessed at Month 24. |
Month 24
|
|
Radiographic evidence of new bone healing.
기간: Month 24
|
Radiographic evidence of new bone healing will be evidenced by X-ray and CT evaluations and assessed at Month 24. |
Month 24
|
|
No recurrence of sinus formation at the treatment site.
기간: Month 24
|
Recurrence of sinus formation at the index site will be assessed by contrast enhanced CT evaluation and Clinical endpoint assessments measured at Month 24. |
Month 24
|
|
No secondary surgical interventions (SSI's) related to the investigational treatment.
기간: Month 24
|
Secondary Surgical interventions (SSI's) related to the investigational treatment will be assessed at Month 24. |
Month 24
|
|
No serious adverse events that are definitely related to genex G.
기간: Month 24
|
Serious adverse events that are definitely related to genex G will be assessed at Month 24. |
Month 24
|
|
Radiographic Evidence of new bone formation and product reabsorption.
기간: Month 24
|
Radiographic evidence of new bone formation and product reabsorption will be evidenced by X-ray and CT evaluations during the course of the trial and recorded on the participants electronic case report form (eCRF). |
Month 24
|
|
Infection resolution evaluated by radiographic assessment and clinical endpoints.
기간: Month 24
|
Radiographic evidence of infection resolution will be evidenced by contrast enhanced CT evaluations and clinical endpoint assessments assessed during the course of the trial and recorded on the participants electronic case report form (eCRF). |
Month 24
|
|
Adverse events including wound problems, reaction to combination product, fracture at treatment site.
기간: Month 24
|
Adverse events including wound problems, reaction to combination product, fracture at treatment site will be assessed during the course of the trial and recorded on the participants electronic case report form (eCRF). |
Month 24
|
|
Secondary Surgical Interventions (SSI's)
기간: Month 24
|
Number of Secondary Surgical Interventions (SSI's) will be assessed during the course of the trial and recorded on the participants electronic case report form (eCRF). |
Month 24
|
|
Number of participants discontinuing therapy prematurely due to a device related event.
기간: Month 24
|
Number of participants discontinuing therapy prematurely due to a device related event will be assessed during the course of the trial and recorded on the participants electronic case report form (eCRF). |
Month 24
|
|
Number of hospitalisations/re-hospitalisation due to treatment site Osteomyelitis.
기간: Month 24
|
Number of hospitalisations/re-hospitalisation due to treatment site Osteomyelitis. |
Month 24
|
|
Quality of Life EQ-5D-5L
기간: Month 24
|
Impact on the participants Quality of Life will be measured by the EQ-5D-5L during the course of the trial and recorded on the participants electronic case report form (eCRF). |
Month 24
|
공동 작업자 및 조사자
수사관
수사관
- 연구 책임자: Keira Watts, PHD, Biocomposites Ltd
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
기타 연구 ID 번호
기타 연구 ID 번호
- 201924
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .